N※N

Get in These Trades/Investments Today

  //stocks-investing.news-articles.net/content/2025/09/18/get-in-these-trades-investments-today.html
  Published in Stocks and Investing on Thursday, September 18th 2025 at 18:06 GMT by investorplace.com
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Get in These Trades: Investments to Watch in September 2025
(InvestorPlace, September 2025)

InvestorPlace’s latest round‑up, released in early September, offers a snapshot of the most promising equity, fixed‑income, and alternative strategies for the month ahead. The article is written for the active investor who wants to capitalize on both macro‑economic trends and micro‑sector catalysts, and it is structured around five key themes: (1) “Digital & Automation” stocks, (2) “Healthcare Innovation” picks, (3) “Renewable Energy & Climate” ETFs, (4) “High‑Yield Corporate Bonds” opportunities, and (5) “Emerging Markets Growth” opportunities. Throughout the piece, the author weaves in recent data releases, Fed commentary, and analyst consensus estimates.

1. Digital & Automation: “Tech‑First” Pivots

The “Digital & Automation” cluster is the article’s headline trade. It highlights NVIDIA (NVDA), Advanced Micro Devices (AMD), and Taiwan Semiconductor Manufacturing Co. (TSM) as the core of a “chip‑stack” strategy. The narrative hinges on three drivers:

1. AI Boom: The author cites the continued acceleration in AI workloads, with a 30 % YoY jump in cloud GPU demand reported by IDC in July.
2. Supply‑Chain Rebalancing: The chip‑maker’s “Advanced Foundry” expansion plans (TSM’s 2025 investment of $30 bn) are described as a positive for long‑term supply security.
3. Margin Expansion: NVIDIA’s operating margin is projected to climb from 30 % in 2024 to 35 % in 2025, while AMD’s margin is forecasted to rise from 12 % to 18 % after cost‑control initiatives.

The article recommends a balanced approach: a 60 % allocation to NVDA, 25 % to AMD, and 15 % to TSM, each bought at a 5‑10 % discount to the 52‑week low. An option overlay is also mentioned—buying a June 20 % OTM call on NVDA with a 12‑month maturity to capture upside while limiting downside.

Follow‑up link: The article links to an InvestorPlace tutorial titled “Using Options for Downside Protection in Tech” (https://investorplace.com/2025/07/options-protection-tech) that walks readers through constructing a “protective put” strategy for the same holdings.

2. Healthcare Innovation: Biotech with a Breakthrough

In the biotech section, InvestorPlace focuses on CRISPR Therapeutics (CRSP), Moderna (MRNA), and Gilead Sciences (GILD). The central thesis is that a wave of genome‑editing trials and mRNA vaccines will deliver a 15–20 % upside over the next 12 months.

Key catalysts cited:

• CRISPR’s Gene‑Editing Pipeline: A phase‑II trial for sickle cell disease reported in the New England Journal of Medicine (July 2025) showing 85 % remission, raising the stock to a “buy” rating with a 24‑month target of $120.
• Moderna’s Expanded mRNA Portfolio: Beyond COVID‑19, Moderna’s pipeline now includes a seasonal flu vaccine and a rare‑disease mRNA therapy. The article notes a 10 % increase in pre‑market revenues for Q4 2024, with expectations of a 30 % rise in 2025 sales.
• Gilead’s Antiviral Maturation: Gilead’s new oral antiviral for hepatitis C has cleared phase‑III, with a projected market capture of 40 % in the U.S. This, coupled with its cash‑rich balance sheet, positions GILD as a “stable growth” play.

InvestorPlace recommends a concentrated allocation: 45 % in CRSP, 35 % in MRNA, and 20 % in GILD, buying at the mid‑price range. The piece also highlights a “short biotech” ETF (ARKX) as an alternative for investors who prefer broader exposure but are wary of individual stock volatility.

Follow‑up link: A referenced article, “Biotech Earnings Outlook: 2025” (https://investorplace.com/2025/08/biotech-earnings-2025), provides deeper earnings analysis and a consensus forecast of a 12 % EPS growth for the sector.

3. Renewable Energy & Climate: The Clean‑Energy Transition

Renewable energy is the author’s “must‑watch” segment, with a focus on NextEra Energy (NEE), the iShares Global Clean Energy ETF (ICLN), and the SPDR S&P Kensho Clean Power ETF (CNRG). The narrative is anchored on policy momentum:

• U.S. Inflation Reduction Act (IRA): The article points out that the IRA’s tax credits for renewable projects are expected to lift NEE’s cash flows by ~25 % over the next five years.
• Global Climate Goals: The United Nations’ latest “Net‑Zero 2050” projections are cited as a tailwind for the clean‑energy index, with a forecast CAGR of 11 % for 2025‑2030.
• Solar & Wind Capacity Additions: The IEA reports a 30 % jump in global solar installations in 2024, which the author claims will boost the ICLN ETF’s performance by at least 18 % in the next quarter.

InvestorPlace recommends an ETF‑centric approach: 50 % in ICLN, 30 % in CNRG, and 20 % in NEE. The author suggests a "long‑only" stance, given the favorable macro backdrop, and advises readers to hold through the “volatility window” expected in early 2026 as the markets digest policy changes.

Follow‑up link: The article contains a link to “Understanding the IRA’s Impact on Energy Stocks” (https://investorplace.com/2025/07/ira-energy-impact), which details how the IRA’s credit structure affects cash‑flow forecasts for utilities and renewable producers.

4. High‑Yield Corporate Bonds: Income with Resilience

For fixed‑income, InvestorPlace presents a “high‑yield, low‑duration” portfolio featuring SPDR Bloomberg Barclays High‑Yield Bond ETF (JNK), iShares iBoxx $ High‑Yield Corporate Bond ETF (HYG), and a short‑duration fixed‑rate fund. The justification is twofold:

• Fed’s Tightening Cycle: As the Fed signals a pause in rate hikes after a 0.75 % increase in July, the article argues that high‑yield bonds will see a reprieve from rate‑sensitive spreads.
• Credit Quality Recovery: The S&P Global Ratings outlook for “Non‑Investment Grade” firms is “Stable” with a 15 % likelihood of a “B‑to‑A” upgrade over the next year.

InvestorPlace recommends a 30‑30‑40 allocation: 30 % in JNK, 30 % in HYG, 40 % in a short‑duration, low‑duration bond fund to reduce duration risk. The author also suggests using a “barbell” strategy—pairing high‑yield bonds with high‑quality, short‑duration bonds to capture income while limiting reinvestment risk.

Follow‑up link: A linked piece, “High‑Yield Bond Investing: Risk & Return” (https://investorplace.com/2025/08/high-yield-bond-risk-return), provides a deeper dive into duration risk and credit spread dynamics.

5. Emerging Markets Growth: Capturing the Next Decade

Emerging markets (EM) are the final pillar of the article, with a focus on iShares MSCI Emerging Markets ETF (EEM), iShares MSCI China ETF (MCHI), and iShares MSCI Brazil ETF (EWZ). The rationale centers on:

• China’s Re‑Opening: The article cites data from the National Bureau of Statistics showing a 4 % increase in retail consumer spending in the second quarter of 2025, implying a 3 % GDP growth projection for the year.
• Brazil’s Fiscal Reforms: New tax reforms are expected to boost private‑sector investment, with an analyst forecast of a 5 % uptick in manufacturing output.
• Global Commodity Demand: China’s steel and copper consumption is projected to grow by 8 % and 6 % respectively, benefiting commodity‑heavy EM equities.

The author recommends a 40 % allocation to EEM (for breadth), a 30 % allocation to MCHI (to capture China’s growth), and a 30 % allocation to EWZ (for Brazil’s commodity play). The article also notes that EM bonds are still volatile, so the focus remains on equities.

Follow‑up link: The piece links to “EM Equity Outlook 2025” (https://investorplace.com/2025/07/em-equity-outlook) for a country‑by‑country analysis.

How to Use This Article

InvestorPlace’s “Get in These Trades” article is not just a list of ticker symbols—it is a framework that ties macro‑policy, sector dynamics, and individual company catalysts together. The author encourages readers to:

1. Build a Core‑Satellite Portfolio: Use ETFs (e.g., ICLN, JNK, EEM) for broad exposure, and add individual stocks (NVDA, CRSP, NEE) as satellites for higher upside.
2. Incorporate Risk Controls: Use options overlays (protective puts or call spreads) on high‑volatility picks, and maintain a short‑duration bond component for income stability.
3. Stay Informed on Policy: Follow Fed minutes and country‑specific policy changes, as these are the main drivers of market movements in the article’s sectors.

By following the article’s logic and the accompanying links, readers can create a diversified portfolio that is positioned to benefit from the key drivers of 2025: AI and automation, biotech breakthroughs, climate policy, high‑yield corporate bonds, and emerging market growth.

Final Thoughts

InvestorPlace’s September 2025 roundup delivers a clear, actionable set of trades that align with the current macro environment. The piece balances high‑growth tech and biotech with income‑generating bonds and broad EM exposure, providing a holistic view for both aggressive and moderate investors. With its concise data points, clear allocation suggestions, and additional learning resources via the embedded links, the article serves as both a quick reference and a deep-dive guide for those looking to capitalize on the next wave of market opportunity.